Effects of naloxone on vasopressin secretion in conscious rats

Evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion

T. Yamada, K. Nakao, Hiroshi Itoh, G. Shirakami, A. Sugawara, Y. Saito, M. Mukoyama, H. Arai, K. Hosoda, S. Shiono, M. Eigyo, A. Matsushita, H. Imura

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The effects of naloxone, an opioid antagonist, on arginine vasopressin (AVP) secretion were examined in conscious unrestrained rats under both basal and stimulated conditions. Intravenous injection of naloxone in a dose of 0.1 mg/kg did not significantly affect the basal plasma AVP level. However, 0.5 or 2.5 mg/kg naloxone significantly raised the basal AVP level in euhydrated rats. Naloxone (0.5 mg/kg) significantly enhanced AVP secretion after 72-h water deprivation. However, the enhancement was more prominent in euhydrated rats than in dehydrated rats. Pretreatment with naloxone (0.5 mg/kg) also significantly prolonged AVP secretion induced by intracerebroventricular injection of angiotensin-II (100 ng). Moreover, naloxone (0.5 mg/kg) significantly increased AVP secretion induced by intracerebroventricular injection of carbachol (10 ng). Naloxone (0.5 mg/kg) altered neither basal blood pressure nor the angiotensin-II-induced pressor response, but augmented the carbachol-induced pressor response. This suggests that facilitation of AVP secretion by naloxone is not due to a reflex mechanism resulting from decreased blood pressure. These results indicate that endogenous opioid peptides exert a tonic inhibitory control on AVP secretion in rats.

Original languageEnglish
Pages (from-to)785-790
Number of pages6
JournalEndocrinology
Volume125
Issue number2
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Opioid Peptides
Arginine Vasopressin
Naloxone
Vasopressins
Carbachol
Angiotensin II
Blood Pressure
Water Deprivation
Injections
Narcotic Antagonists
Intravenous Injections
Reflex

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of naloxone on vasopressin secretion in conscious rats : Evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion. / Yamada, T.; Nakao, K.; Itoh, Hiroshi; Shirakami, G.; Sugawara, A.; Saito, Y.; Mukoyama, M.; Arai, H.; Hosoda, K.; Shiono, S.; Eigyo, M.; Matsushita, A.; Imura, H.

In: Endocrinology, Vol. 125, No. 2, 1989, p. 785-790.

Research output: Contribution to journalArticle

Yamada, T, Nakao, K, Itoh, H, Shirakami, G, Sugawara, A, Saito, Y, Mukoyama, M, Arai, H, Hosoda, K, Shiono, S, Eigyo, M, Matsushita, A & Imura, H 1989, 'Effects of naloxone on vasopressin secretion in conscious rats: Evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion', Endocrinology, vol. 125, no. 2, pp. 785-790.
Yamada, T. ; Nakao, K. ; Itoh, Hiroshi ; Shirakami, G. ; Sugawara, A. ; Saito, Y. ; Mukoyama, M. ; Arai, H. ; Hosoda, K. ; Shiono, S. ; Eigyo, M. ; Matsushita, A. ; Imura, H. / Effects of naloxone on vasopressin secretion in conscious rats : Evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion. In: Endocrinology. 1989 ; Vol. 125, No. 2. pp. 785-790.
@article{2ca63abdcbf74ec0ac40e288f3b95bc2,
title = "Effects of naloxone on vasopressin secretion in conscious rats: Evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion",
abstract = "The effects of naloxone, an opioid antagonist, on arginine vasopressin (AVP) secretion were examined in conscious unrestrained rats under both basal and stimulated conditions. Intravenous injection of naloxone in a dose of 0.1 mg/kg did not significantly affect the basal plasma AVP level. However, 0.5 or 2.5 mg/kg naloxone significantly raised the basal AVP level in euhydrated rats. Naloxone (0.5 mg/kg) significantly enhanced AVP secretion after 72-h water deprivation. However, the enhancement was more prominent in euhydrated rats than in dehydrated rats. Pretreatment with naloxone (0.5 mg/kg) also significantly prolonged AVP secretion induced by intracerebroventricular injection of angiotensin-II (100 ng). Moreover, naloxone (0.5 mg/kg) significantly increased AVP secretion induced by intracerebroventricular injection of carbachol (10 ng). Naloxone (0.5 mg/kg) altered neither basal blood pressure nor the angiotensin-II-induced pressor response, but augmented the carbachol-induced pressor response. This suggests that facilitation of AVP secretion by naloxone is not due to a reflex mechanism resulting from decreased blood pressure. These results indicate that endogenous opioid peptides exert a tonic inhibitory control on AVP secretion in rats.",
author = "T. Yamada and K. Nakao and Hiroshi Itoh and G. Shirakami and A. Sugawara and Y. Saito and M. Mukoyama and H. Arai and K. Hosoda and S. Shiono and M. Eigyo and A. Matsushita and H. Imura",
year = "1989",
language = "English",
volume = "125",
pages = "785--790",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Effects of naloxone on vasopressin secretion in conscious rats

T2 - Evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion

AU - Yamada, T.

AU - Nakao, K.

AU - Itoh, Hiroshi

AU - Shirakami, G.

AU - Sugawara, A.

AU - Saito, Y.

AU - Mukoyama, M.

AU - Arai, H.

AU - Hosoda, K.

AU - Shiono, S.

AU - Eigyo, M.

AU - Matsushita, A.

AU - Imura, H.

PY - 1989

Y1 - 1989

N2 - The effects of naloxone, an opioid antagonist, on arginine vasopressin (AVP) secretion were examined in conscious unrestrained rats under both basal and stimulated conditions. Intravenous injection of naloxone in a dose of 0.1 mg/kg did not significantly affect the basal plasma AVP level. However, 0.5 or 2.5 mg/kg naloxone significantly raised the basal AVP level in euhydrated rats. Naloxone (0.5 mg/kg) significantly enhanced AVP secretion after 72-h water deprivation. However, the enhancement was more prominent in euhydrated rats than in dehydrated rats. Pretreatment with naloxone (0.5 mg/kg) also significantly prolonged AVP secretion induced by intracerebroventricular injection of angiotensin-II (100 ng). Moreover, naloxone (0.5 mg/kg) significantly increased AVP secretion induced by intracerebroventricular injection of carbachol (10 ng). Naloxone (0.5 mg/kg) altered neither basal blood pressure nor the angiotensin-II-induced pressor response, but augmented the carbachol-induced pressor response. This suggests that facilitation of AVP secretion by naloxone is not due to a reflex mechanism resulting from decreased blood pressure. These results indicate that endogenous opioid peptides exert a tonic inhibitory control on AVP secretion in rats.

AB - The effects of naloxone, an opioid antagonist, on arginine vasopressin (AVP) secretion were examined in conscious unrestrained rats under both basal and stimulated conditions. Intravenous injection of naloxone in a dose of 0.1 mg/kg did not significantly affect the basal plasma AVP level. However, 0.5 or 2.5 mg/kg naloxone significantly raised the basal AVP level in euhydrated rats. Naloxone (0.5 mg/kg) significantly enhanced AVP secretion after 72-h water deprivation. However, the enhancement was more prominent in euhydrated rats than in dehydrated rats. Pretreatment with naloxone (0.5 mg/kg) also significantly prolonged AVP secretion induced by intracerebroventricular injection of angiotensin-II (100 ng). Moreover, naloxone (0.5 mg/kg) significantly increased AVP secretion induced by intracerebroventricular injection of carbachol (10 ng). Naloxone (0.5 mg/kg) altered neither basal blood pressure nor the angiotensin-II-induced pressor response, but augmented the carbachol-induced pressor response. This suggests that facilitation of AVP secretion by naloxone is not due to a reflex mechanism resulting from decreased blood pressure. These results indicate that endogenous opioid peptides exert a tonic inhibitory control on AVP secretion in rats.

UR - http://www.scopus.com/inward/record.url?scp=0024389381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024389381&partnerID=8YFLogxK

M3 - Article

VL - 125

SP - 785

EP - 790

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -